Selank

The Selank evidence base cited here is 9 sources — 2 clinical, 5 preclinical. Its strongest evidence is human — 2 clinical studies, most recently 2014 ("Comparison of Selank and Phenazepam in Anxiety Disorders"). Regulatory status: Approved in Russia.

Selank and Semax emerged from the same Russian peptide research program, are both given intranasally, and are the most commonly paired nootropics in the community — so they are usually discussed together. They are complementary rather than interchangeable.

A useful framing: Selank is the stabilizer (it protects cognitive function under stress by lowering anxiety) and Semax is the accelerator (it pushes cognition forward with mild stimulation). The two are frequently combined for a balanced anxiolytic-nootropic profile, though formal combination studies are limited.

• Selank (TP-7) is a synthetic heptapeptide (Thr-Lys-Pro-Arg-Pro-Gly-Pro, MW ≈ 751.9 Da) engineered in 1990s Russia by extending the natural immune peptide tuftsin with a Pro-Gly-Pro tail to make it metabolically stable.
• It is an anxiolytic and nootropic that works through several systems at once — GABAergic and serotonergic modulation, BDNF-driven neuroplasticity, enkephalin stabilization, and immune signaling — rather than saturating a single receptor.
• Unusually for a nootropic peptide, it has actual human clinical trials: head-to-head comparisons against the benzodiazepines medazepam and phenazepam showed comparable anxiety reduction WITHOUT sedation, tolerance, or withdrawal.

Selank is a synthetic seven-amino-acid peptide developed in Russia as an anxiolytic and nootropic. It is a stabilized analog of tuftsin, a naturally occurring immune peptide, and exerts anti-anxiety, cognitive, and immunomodulatory effects through several distinct neurochemical pathways at once.

What makes it notable among research peptides is that it crossed from preclinical work into actual clinical prescription — it has been an approved anxiolytic in Russia since 2009. In the same studies it matched benzodiazepines on anxiety reduction but without the sedation, cognitive dulling, tolerance, or dependence that limit long-term benzodiazepine use.

It is not FDA-approved and has no approved label outside Russia. Everything below is research context synthesized from the published literature — not medical guidance, and not instructions for human use.

Selank (development code TP-7) is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro and a molecular weight of roughly 751.9 Da. It is a stabilized derivative of tuftsin — a natural tetrapeptide (Thr-Lys-Pro-Arg) released when the body cleaves the Fc region of immunoglobulin G. Tuftsin is an innate-immunity signal that boosts the phagocytic activity of macrophages and neutrophils, but it is useless as a drug on its own because it is degraded within seconds in plasma.

In the 1990s a team led by Nikolai Myasoedov at the Institute of Molecular Genetics of the Russian Academy of Sciences, working with the V.V. Zakusov Research Institute of Pharmacology, appended a Pro-Gly-Pro tripeptide to tuftsin's C-terminus. The result kept tuftsin's immune properties, gained pronounced neurotropic activity, and resisted enzymatic breakdown far better than the parent peptide.

Selank was approved by the Russian Ministry of Health in 2009 and is sold there by prescription as Selanc, a 0.15% metered-dose nasal spray, for generalized anxiety disorder and as an adjunct for neurasthenic conditions; it is reportedly available in Ukraine as well. Its dual heritage — immunology from tuftsin, neuropsychopharmacology from the program that produced it — gives it a profile unlike any single Western anxiolytic: it is neither a benzodiazepine nor an SSRI, but a peptide that nudges several systems simultaneously while preserving immune function.

Selank's pharmacology is multi-target. Rather than maximally engaging one receptor system, it modulates at least four at moderate intensity — which likely explains both its broad effects and its unusually clean side-effect profile.

There is no FDA-approved dosing for Selank. The figures below describe the approved Russian protocol and what appears in the research literature and community reports, included for research context only — not as instructions for use.

Russian clinical practice uses 14-day courses with one-month breaks; published data did not show tolerance developing within those courses. Continuous, uncycled use is sometimes described anecdotally but is not supported by trial data.

Reported effects reflect Selank's dual pharmacology: rapid GABAergic/enkephalin-mediated anxiolysis layered with slower BDNF-driven neuroplastic change.

Selank's evidence is unusual for a nootropic/anxiolytic peptide in that it includes human clinical trials — albeit conducted within the Russian clinical research system — on top of an extensive preclinical dataset spanning anxiety, cognition, and immune function.

Bottom line: promising and clinically suggestive, but the certainty is lower than for drugs that have cleared FDA or EMA review. No Western regulator has rejected Selank on safety grounds — it simply has not been submitted for approval outside Russia.

Selank's multi-target mechanism makes it a logical partner for compounds hitting complementary pathways. Formal interaction data is effectively nonexistent outside the diazepam-synergy study, so the notes below are research context, not protocol advice — and establishing individual response to Selank alone before adding anything is the prudent approach.

• Selank + Semax — the most commonly discussed pairing: Selank stabilizes via GABA/enkephalin pathways while Semax stimulates via dopaminergic activation and BDNF, yielding calm alertness rather than jittery stimulation or sedated calm. See the Selank vs. Semax comparison above.
• Selank + Noopept — additive neurotrophin support (Noopept also modulates BDNF/NGF) plus anxiolysis; both can be given intranasally.
• Selank + Magnesium L-threonate — converges on GABAergic support through a different (NMDA-modulating) mechanism that crosses the blood-brain barrier.
• Selank + adaptogens (ashwagandha, rhodiola) — may complement neurotransmitter-level anxiolysis by lowering upstream HPA-axis/cortisol signaling; no formal interaction studies exist.

N-Acetyl Selank Amidate is a chemically modified Selank carrying an acetyl group on the N-terminus and an amide on the C-terminus. Protecting both ends from exopeptidase degradation is reported to improve metabolic stability and blood-brain-barrier penetration and to extend the effective half-life (estimated ~4–6 hours versus standard Selank's rapid parent-compound breakdown), with bioavailability reported ~30–50% higher — allowing lower effective doses. It is not an approved pharmaceutical in any jurisdiction and exists only as a research compound.

Pre-made nasal spray (as marketed in Russia) needs no preparation — it is stored refrigerated at 2–8°C and used within the manufacturer's window (typically ~30 days after opening). Lyophilized powder requires reconstitution; the following reflects general laboratory peptide handling only.

• Let the vial reach room temperature; use bacteriostatic water (0.9% benzyl alcohol) as the vehicle.
• Add water slowly down the interior vial wall and swirl gently until clear and colorless — do not shake.
• Common ratio: 5 mg Selank + 5 mL bacteriostatic water = 1 mg/mL.
• Lyophilized powder: store at −20°C long-term (stable at 2–8°C for several months); protect from light and moisture.
• Reconstituted solution: store at 2–8°C, use within ~28 days; discard if cloudy, discolored, or containing particles.

Selank has one of the cleanest side-effect profiles of any anxiolytic studied clinically — a tolerability advantage over benzodiazepines and SSRIs that recurs throughout the Russian clinical literature.

No serious adverse events have been attributed to Selank in published clinical literature. The FDA has raised a general (theoretical) immunogenicity concern about compounded peptides, but no immunogenicity-related events from Selank have been published. As with any unregulated peptide, sourcing risks — contamination, degradation, mislabeling — are separate from the compound's intrinsic safety, so third-party COA verification matters.

Selank's regulatory standing differs sharply by jurisdiction. For a broader overview of where research peptides sit legally, see the peptide legality guide.

• Russia: approved prescription medication since 2009 (Selanc 0.15% nasal spray) for GAD and neurasthenic conditions.
• United States: not FDA-approved for any indication; not DEA-scheduled. In September 2024, Selank acetate (TP-7) was removed from the FDA's Category 2 bulk drug substances list because the nominators withdrew their nominations — not because the FDA cleared it. Its status for 503A/503B compounding remains under review pending Pharmacy Compounding Advisory Committee evaluation.
• EU, UK, Canada, Australia: not approved by the EMA, MHRA, Health Canada, or TGA; a research-compound gray area, with personal-import rules varying by jurisdiction.

The asymmetry between Russia and Western regulators reflects differing trial standards and regulatory pathways, not a specific safety rejection. Research-grade Selank is for laboratory research only and is not intended for human use.

Selank is not explicitly named on the 2026 WADA Prohibited List, but tested athletes should be cautious. WADA's catch-all S0 category prohibits any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use — and because Selank is not approved by the FDA, EMA, or other major Western authorities, it could plausibly be captured under S0 even though it is approved in Russia. How S0 applies when a substance is approved in one country but not the athlete's jurisdiction has not been definitively resolved for Selank specifically. 'Not explicitly banned' does not mean 'permitted' — athletes subject to testing should clear any use with their governing body first.

All citations link to the original source (PubMed, journal site, or regulatory filing). Independent research database — no vendor influence on what's cited.